Atlas Trials

A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma

Clinical trial NCT02616640 · COMPLETED

Trial details

NCT number
NCT02616640
Sponsor
Celgene
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Multiple Myeloma
Start date
2016-01-11
Primary completion
2018-11-23
Enrollment
114

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.